Abstract
Recent clinical studies have suggested that treatment with atypical antipsychotic drugs, such as olanzapine, may slow progressive changes in brain structure in patients with schizophrenia. To investigate the possible neural basis of this effect, we sought to determine whether treatment with olanzapine would inhibit the loss of hippocampal neurons associated with the administration of the excitotoxin, kainic acid, in neonatal rats. At post-natal day 7 (P7), rats were exposed to kainic acid via intracerebroventricular administration. Neuronal loss within the CA2 and CA3 subfields of the hippocampus and neurogenesis within the dentate gyrus of the hippocampus were then assessed at P14 by Fluoro-Jade B and BrdU labeling, respectively. Daily doses of olanzapine (2, 6, or 12 mg/day), haloperidol (1.2 mg/kg), melatonin (10 mg/kg), or saline were administered between P7 and P14. Melatonin is an anti-oxidant drug and was included in this study as a positive control, since it has been observed to have neuroprotective effects in a variety of animal models. The highest dose of olanzapine and melatonin, but not haloperidol, ameliorated the hippocampal neuronal loss triggered by kainic acid administration. However, drug administration did no...Continue Reading
References
Dec 1, 1989·Archives of General Psychiatry·T J CrowG W Roberts
Jul 1, 1987·Archives of General Psychiatry·D R Weinberger
Oct 1, 1995·Journal of Neurotrauma·E M JohnsonC Y Hsu
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Feb 1, 1997·Behavioural Brain Research·G L WenkW Danysz
Sep 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·J BengzonO Lindvall
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·P H SchlesingerS J Korsmeyer
Dec 31, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·N B FarberJ W Olney
Dec 8, 1998·The American Journal of Psychiatry·B T Woods
Apr 23, 1999·Journal of Neuroscience Research·X M LiA A Boulton
Jan 11, 2000·Journal of Psychiatric Research·J W OlneyN B Farber
Sep 19, 2000·International Clinical Psychopharmacology·S H HamiltonA Breier
Oct 4, 2000·Archives of General Psychiatry·R M Sapolsky
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·P M ThompsonJ L Rapoport
Nov 27, 2001·Neuroscience·C WangK M Johnson
Jun 14, 2002·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Michael V JohnstonHenrik Hagberg
Nov 20, 2002·Neuroreport·Silvia ZucchiniMichele Simonato
Nov 28, 2002·Neuroscience·K SriramJ P O'Callaghan
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark E BardgettJohn G Csernansky
Jan 23, 2003·Synapse·Ramamohana R JonnalaJerry J Buccafusco
Apr 22, 2004·Neuroscience·A Riba-Bosch, J Pérez-Clausell
Aug 25, 2004·Neurotoxicity Research·Ananth ChandrasekaranCharanjit Kaur
Apr 6, 2005·Archives of General Psychiatry·Jeffrey A LiebermanUNKNOWN HGDH Study Group
Citations
Jul 8, 2010·European Archives of Psychiatry and Clinical Neuroscience·Ralf BrischBernhard Bogerts
Dec 12, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Halil Ibrahim OnderFatih Mehmet Gokce
Sep 12, 2014·Journal of Exercise Rehabilitation·Jin Woo ChungTae-Woon Kim
Oct 21, 2015·Pharmacological Reports : PR·Ewa RojczykRyszard Wiaderkiewicz
Mar 7, 2012·Neuroscience·J ParkS Y Yoon
Feb 22, 2008·Journal of Pineal Research·Kerry RennieBruce A Pappas
Oct 22, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Martin HýžaTomáš Kašpárek
Oct 17, 2008·Pharmacological Reviews·Jeffrey A LiebermanJohn G Csernansky
Aug 14, 2019·Molecular Biology Reports·Mohammad AsghariSeyed Jalal Hosseinimehr
Aug 13, 2020·International Journal of Molecular Sciences·Joseph Wai-Hin LeungBenson Wui-Man Lau